Rosine Guimbaud
0000-0002-8344-1762
Publication & Citation Trends
Publications
0 total
Perioperative treatment in resectable gastric cancer with spartalizumab in combination with fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT): Results from the GASPAR phase 2 study.
Cited by 0
Semantic Scholar
From clusters to clinic: An 8-gene signature combined with mucinous component stratifies benefit of anti-CTLA-4 addition to anti-PD-1 in dMMR/MSI-H metastatic colorectal cancer
Cited by 0
Semantic Scholar
Author Correction: Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast–ovarian cancer susceptibility locus
Cited by 0
Semantic Scholar
Is survival influenced by metastatic site in synchronous metastatic pancreatic adenocarcinoma (PDAC)? A prospective real-world BACAP study
Cited by 2
Semantic Scholar
Prognostic impact of the BRAF V600E mutation in patients with MSI-high metastatic colorectal cancer treated with immune checkpoint inhibitors.
Cited by 4
Semantic Scholar
Immune checkpoint inhibitor (ICI) reuse after failure of first-line ICI in patients with metastatic dMMR/MSI gastrointestinal cancers: The INFLATE study.
Cited by 0
Semantic Scholar
Early treatment discontinuation in patients with deficient mismatch repair or microsatellite instability high metastatic colorectal cancer receiving immune checkpoint inhibitors OA
Cited by 7
Semantic Scholar
Neoadjuvant pembrolizumab with a watch‑and‑wait strategy for localized MSI/dMMR colon cancer: Study protocol for a randomized GERCOR 109 - PRODIGE 84 phase II trial (PREMICES).
Cited by 1
Semantic Scholar
Research Topics
Colorectal Cancer Treatments and Studies
(140)
Genetic factors in colorectal cancer
(85)
Gastric Cancer Management and Outcomes
(65)
Pancreatic and Hepatic Oncology Research
(53)
Cancer Genomics and Diagnostics
(45)
Affiliations
Centre National de la Recherche Scientifique
DuPont (United States)
University of Debrecen
Université Toulouse III - Paul Sabatier
Université de Bordeaux